Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice

Am J Gastroenterol. 2015 Mar;110(3):472-3. doi: 10.1038/ajg.2015.10.

Authors

Giorgia Bodini¹, Edoardo G Giannini¹, Edoardo V Savarino², Vincenzo Savarino¹

Affiliations

¹ Gastroenterology Unit, Department of Internal Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, University of Genoa, Genoa, Italy.
² Division of Gastroenterology, Department of Surgery and Gastroenterology, University of Padua, Padua, Italy.

PMID: 25743715
DOI: 10.1038/ajg.2015.10

No abstract available

Publication types

Letter
Comment

MeSH terms

Algorithms*
Anti-Inflammatory Agents / pharmacokinetics*
Antibodies, Monoclonal, Humanized / pharmacokinetics*
Female
Humans
Inflammatory Bowel Diseases / drug therapy*
Male

Substances

Anti-Inflammatory Agents
Antibodies, Monoclonal, Humanized